Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
ASRS v1.1 Part A is a brief 6-question screening tool for adult ADHD symptom patterns. It is designed for first-line identification of individuals who may benefit from full diagnostic ADHD assessment.
Formula: Common positive screen when >=4 of 6 items cross item-specific thresholds (Q1-4: Sometimes/Often/Very often; Q5-6: Often/Very often).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The patient self-reports how often they experienced each of 6 symptoms over the past 6 months using a 5-point scale (Never/Rarely/Sometimes/Often/Very Often). Items cover inattention (Q1-4) and hyperactivity/impulsivity (Q5-6) domains.
Each item has a threshold frequency that marks the 'shaded' (positive) zone: for Q1-4 the threshold is 'Sometimes' or higher; for Q5-6 the threshold is 'Often' or higher. Count how many items fall in the shaded zone.
If 4 or more of the 6 Part A items are in the shaded zone, the screen is positive and warrants comprehensive ADHD evaluation including clinical interview, collateral history, functional impairment assessment, and ruling out alternative explanations.
Primary Care Physicians
Adult ADHD is prevalent (2.5-5%) and frequently undiagnosed. ASRS-v1.1 provides a validated, standardized first-step screening tool for primary care providers before referring for comprehensive ADHD evaluation.
Psychiatrists & Psychologists
At mental health intake, ASRS-v1.1 efficiently screens for ADHD as part of comprehensive assessment, especially when inattention, executive dysfunction, or emotional dysregulation are presenting complaints.
Occupational Health & EAP Counselors
Adults with undiagnosed ADHD have significantly higher rates of job instability, workplace accidents, and reduced productivity. EAP counselors use ASRS-v1.1 to identify ADHD as a contributing factor when workplace performance problems are reported.
College Disability Services Staff
Many adults receive their first ADHD diagnosis when academic demands increase in college. Disability services offices use ASRS-v1.1 to screen students seeking accommodations for attention and organizational difficulties.
Psychiatrists & Primary Care Physicians
ASRS-v1.1 can be used serially to monitor symptom burden in response to pharmacotherapy (stimulants, atomoxetine) and behavioral interventions over time, providing a standardized treatment outcome measure.
A positive ASRS Part A does not diagnose ADHD. Diagnosis requires clinical interview establishing symptom severity, childhood onset (symptoms must have been present before age 12), functional impairment across multiple settings, and exclusion of alternative diagnoses (anxiety, mood disorders, sleep disorders, thyroid disease).
Adult ADHD affects approximately 2.5-5% of adults, but many were not diagnosed in childhood, particularly women and those with predominantly inattentive presentations. Adults may have developed compensatory strategies that masked symptoms for decades before recognition.
Approximately 50% of adults with ADHD have comorbid anxiety disorders, 38% have depression, and 20% have bipolar disorder. These comorbidities must be identified and treated concurrently — treating ADHD alone without addressing comorbid depression often yields suboptimal outcomes.
Women with ADHD more frequently present with inattentive symptoms (forgetting, disorganization, difficulty completing tasks) rather than the hyperactive/impulsive presentation more common in men. This has historically led to significant underdiagnosis of ADHD in women and girls.
Stimulant medications (amphetamines, methylphenidate) are Schedule II controlled substances with misuse potential. Before prescribing, assess for substance use disorders and consider non-stimulant alternatives (atomoxetine, guanfacine, viloxazine) for high-risk patients.
Non-stimulant medications include atomoxetine (SNRi, FDA-approved for adult ADHD), guanfacine ER (alpha-2 agonist), and viloxazine ER (norepinephrine reuptake inhibitor). Onset is slower (2-4 weeks) than stimulants but they are non-scheduled and appropriate when stimulant misuse is a concern.
Cognitive behavioral therapy (CBT) focused on ADHD-specific skill-building (task management, time estimation, emotion regulation) significantly improves functional outcomes when combined with pharmacotherapy versus medication alone.
DSM-5 requires symptoms to have been present before age 12 and to cause impairment in two or more settings (work, home, social). Adult patients often describe 'always being this way' — this developmental history is a critical diagnostic requirement distinguishing ADHD from acquired attention difficulties.
Adults with ADHD have approximately 2-3× higher rates of substance use disorders compared to the general population. Paradoxically, treating ADHD with stimulants reduces the risk of developing substance use disorders in adolescents and adults, contrary to common concerns.
Anxiety (worry, distraction), depression (concentration problems, low motivation), bipolar disorder (racing thoughts, impulsivity), and sleep disorders (inattention from fatigue) can all produce positive ASRS screens without true ADHD. Clinical differentiation is essential before starting ADHD-specific treatment.
ASRS-v1.1 developed by Kessler et al. (Psychol Med 2005) for WHO Adult ADHD Initiative. Part A sensitivity 68.7%, specificity 99.5% for DSM-IV ADHD in a clinical sample. Validated in multiple populations including primary care and general population. CHADD and AHRQ recommend structured screening for adult ADHD using ASRS. Adult ADHD prevalence meta-analysis: Simon et al. (Eur Psychiatry 2009) — 2.5% worldwide. Faraone et al. (Nat Rev Dis Primers 2021) reviewed adult ADHD epidemiology and management.
A positive ASRS Part A pattern suggests elevated adult ADHD symptom burden and supports formal clinical ADHD assessment.
Use in adult behavioral-health or primary-care intake when inattention/executive symptoms are reported.
ASRS is self-reported and screening-oriented. It does not establish diagnosis, childhood-onset history, or functional pervasiveness across settings on its own.
For related assessments, see PHQ-9, GAD-7 and MDI Depression Scale.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Free PHQ-9 depression screening questionnaire. Take the Patient Health Questionnaire-9 to assess depression severity with instant scoring and interpretation. Also screen for anxiety with [GAD-7](/tools/gad7).
OpenMental HealthFree GAD-7 anxiety screening questionnaire. Take the Generalized Anxiety Disorder 7-item scale to assess anxiety severity with instant scoring and interpretation. Also screen for depression with [PHQ-9](/tools/phq9).
OpenMental HealthScreen for depression using the WHO-endorsed Major Depression Inventory (MDI). A 10-item self-report questionnaire scoring 0–50.
Open